Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.62 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.62 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eniporide SCHEMBL6619621 | 0.80 | SLC9A1 (0.63) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL6623628 | 0.79 | SLC9A1 (0.62) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL6923112 | 0.78 | SLC9A1 (0.67) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL6927272 | 0.77 | SLC9A1 (0.63) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL29359767 | 0.77 | SLC9A1 (0.95) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL29359307 | 0.77 | SLC9A1 (1.00) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL6619624 | 0.77 | SLC9A1 (1.00) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL6623631 | 0.73 | SLC9A1 (0.73) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL6903753 | 0.69 | SLC9A1 (0.63) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL8032919 | 0.69 | SLC9A1 (0.72) | SLC9A1SLC9A3SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015189236-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING CD95-MEDIATED CELL MOTILITY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-12-17 | — | — | WO | disclosed |
| CN-1370531-A | Combined therapy | PFIZER PRODUCT CO (US) | 2002-09-25 | — | — | CN | disclosed |
| EP-1226830-A2 | Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia | Pfizer Products Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020099075-A1 | COMBINATION THERAPY | TRACEY WAYNE R (US) | 2002-07-25 | — | — | US | disclosed |
| US-6423705-B1 | FOR ISCHEMIA BY ADMINISTERING AN NHE-1 INHIBITOR AND A SECOND COMPOUND SELECTED FROM COMPLEMENT MODULATOR, METABOLIC MODULATOR, ANTIAPOPTOTIC AGENT, NITRIC OXIDE SYNTHASE-RELATED AGENT, AND AN ENZYME/PROTEIN MODULATOR | PFIZER INC. | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099075-A1 | COMBINATION THERAPY | TFPI, SLC9A1, TFPI2 | SLC9A1 2/4885SLC9A3 16/4885SLC9A2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.